Page last updated: 2024-11-10

carboprost

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Carboprost: A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of PREGNANCY. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

carboprost : Prostaglandin F2alpha in which the hydrogen at position 15 is substituted by methyl (S configuration). It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281075
CHEMBL ID1237122
CHEBI ID3403
SCHEMBL ID433553
MeSH IDM0003399

Synonyms (80)

Synonym
carboprostum
CHEBI:3403 ,
15(s)-15-methyl-pgf2alpha
(5z,13e,15s)-9alpha,11alpha,15-trihydroxy-15-methylprosta-5,13-dien-1-oic acid
15(s)-15-methylprostaglandin f2alpha
15-methyl-pgf2-alpha
59286-19-0
(5z,9alpha,11alpha,13e,15s)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oic acid
prosta-5,13-dien-1-oic acid, 15-methyl-9,11,15-trihydroxy-, (5z,9-alpha,11-alpha,13e,15s)-, (+-)-
15(s)-15-methyl pgf2-alpha
15-me-pgf2-alpha
15-methylprostaglandin f2alpha
9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oic acid (5z,9alpha,11alpha,13e,15s)-
15-methyl prostaglandin f2alpha
(15s)-15-methylprostaglandin f2alpha
(15s)15 methyl prostaglandin f2-alpha
15-methylprostaglandin f2-alpha
u 32921
15-methyl pgf2-alpha
(15s)-15-methylprostaglandin f(sub 2alpha)
carboprostum [inn-latin]
(5z,9-alpha,11-alpha,13e,15s)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oic acid
(e,z)-(1r,2r,3r,5s)-7-(3,5-dihydroxy-2-((3s)-(3-hydroxy-3-methyl-1-octenyl))cyclopentyl)-5-heptenoic acid
prostin 15m
15(s)-15-methyl-prostaglandin f2-alpha
prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5z,9alpha,11alpha,13e,15s)-
15-methyl-pgf2-alpha (alpha and beta)
brn 2949991
methyl-pgf2-alpha
15(s)-methylprostaglandin f2-alpha
carboprost [usan:inn:ban]
(15s)-15-methyl-pgf2alpha
15-methyl-15s-pgf2alpha
9s,11r,15s-trihydroxy-15-methyl-5z,13e-prostadienoic acid
LMFA03010080
15-methyl-15s-prostaglandin f2alpha
C06872
carboprost
35700-23-3
carboprost (usan/inn)
D02343
u-32921
15 methylprostaglandin f2alpha
(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3s)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid
unii-7b5032xt6o
u-32,921
7b5032xt6o ,
15-methylprostaglandin f2.alpha.
15-methyl-pgf2.alpha.
CHEMBL1237122
(15s)-15-methyl-pgf2.alpha.
S9327
prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5z,9.alpha.,11.alpha.,13e,15s)-
carboprost [mi]
carboprost [vandf]
carboprost [mart.]
(5z,9.alpha.,11.alpha.,13e,15s)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oic acid
(15s)-15-methylprostaglandin f2.alpha.
(15s)-15-methylprostaglandin f(sub 2.alpha.)
carboprost [inn]
carboprost [who-dd]
(e,z)-(1r,2r,3r,5s)-7-[3,5-dihydroxy-2-[(3s)-(3-hydroxy-3-methyl-1-octenyl)]cyclopentyl]-5-heptenoic acid
15-methylprostaglandin f2beta, (15s)-
carboprost [usan]
SCHEMBL433553
DLJKPYFALUEJCK-IIELGFQLSA-N
HMS3648F18
DTXSID4022739 ,
AKOS027326498
Q5038067
SR-01000946499-1
sr-01000946499
CCG-268274
MS-25920
CS-0099506
HY-128428
g02ad04
dtxcid102739
carboprost (mart.)
carboprostum (inn-latin)

Research Excerpts

Overview

Carboprost tromethamine is a synthetic prostaglandin derivative. It can effectively promote law contraction of the uterus and significantly reduce the amount of bleeding during and after delivery.

ExcerptReferenceRelevance
"Carboprost tromethamine is a synthetic prostaglandin derivative, which can effectively promote law contraction of the uterus and significantly reduce the amount of bleeding during and after delivery. "( Effect of carboprost tromethamine in prevention of postpartum hemorrhage in cesarean section.
Cui, Z; Lifan, C; Ling, Z; Yao, L, 2018
)
2.33
"Carboprost trometamol is a more potent uterotonic drug than methylergometrine. "( Carboprost trometamol in the management of the third stage of labor.
Abdel-Aleem, H; Abdel-Wahab, HA; Abol-Oyoun, EM; Kamel, HS; Moustafa, SA, 1993
)
3.17

Actions

ExcerptReferenceRelevance
"Carboprost plays an important role in managing refractory uterine atony and severe postpartum hemorrhage. "( Sufentanil for carboprost-induced adverse reactions during cesarean delivery under combined spinal-epidural anesthesia.
Bai, P; Guo, J; He, T; Hu, Q; Li, H; Xiao, X; Yang, P; Zhang, L, 2023
)
2.71

Toxicity

ExcerptReferenceRelevance
" Adverse gastrointestinal events were recorded more often in the Hemabate group."( A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage.
Gordon, H; Lamont, RF; Logue, M; Morgan, DJ, 2001
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" In amniotic fluid the half-life was between 31 and 37 hours."( Pharmacokinetics of prostaglandins.
Bygdeman, M, 2003
)
0.32

Compound-Compound Interactions

Carboprost aminobutyriol combined with oxytocin may be beneficial to infant outcome and uterine involution after cesarean section. Electroacupuncture combined with tropisetron could effectively relieve carboprost tromethamine-induced nausea and vomiting.

ExcerptReferenceRelevance
"Medical regimens using mifepristone in combination with prostaglandins have been widely available for women undergoing termination of pregnancy (TOP) at 10-16 weeks' gestation in China."( Mifepristone in combination with prostaglandins for termination of 10-16 weeks' gestation: a systematic review.
Chen, QJ; Cheng, LN; Hong, QQ; Hou, SP; Huang, YM; Meads, C; Zhu, HP, 2011
)
0.37
"We evaluated the efficacy of electroacupuncture combined with tropisetron in treating carboprost tromethamine-induced nausea and vomiting during cesarean section under lumbar anesthesia."( Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia.
Chang, Y; Qu, M; Wei, Q; Yang, Q; Yao, Z; Yu, L, 2021
)
1.08
"Our study suggested that electroacupuncture combined with tropisetron could effectively relieve carboprost tromethamine-induced nausea and vomiting during cesarean section under lumbar anesthesia."( Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia.
Chang, Y; Qu, M; Wei, Q; Yang, Q; Yao, Z; Yu, L, 2021
)
1.07
"No well-designed and systematic evaluation of the efficacy and safety of leonurus japonicus injection (LJI) in combination with carboprost tromethamine has been found."( Efficacy of carboprost tromethamine combined with leonurus japonicus for prevention of postpartum hemorrhage in high-risk pregnant women: A protocol for systematic review and meta-analysis.
Cao, Y; Zong, F, 2021
)
1.21
"" Any cohort studies that assessed the efficacy and safety of carboprost tromethamine combined with LJI for the prevention of postpartum hemorrhage would be included."( Efficacy of carboprost tromethamine combined with leonurus japonicus for prevention of postpartum hemorrhage in high-risk pregnant women: A protocol for systematic review and meta-analysis.
Cao, Y; Zong, F, 2021
)
1.24
"The study aims to explore the effect of low-frequency electric pulse technique combined with carboprost methylate suppositories on recovery of gastrointestinal function and postoperative complications of patients with scarred uterus undergoing secondary cesarean section (C-section)."( Effect of Low-Frequency Electric Pulse Technique Combined with Carboprost Methylate Suppositories on Recovery of Gastrointestinal Function and Postoperative Complications of Patients with Scarred Uterus Undergoing Secondary Cesarean Section.
Jiao, R; Li, M; Liu, Y; Yan, J; Zhao, L, 2021
)
1.08
" Carboprost aminobutyriol combined with oxytocin may be beneficial to infant outcome and uterine involution after cesarean section."( Cohort Study Summary of the Effects of Carboprost Tromethamine Combined with Oxytocin on Infant Outcome, Postpartum Hemorrhage and Uterine Involution of Parturients Undergoing Cesarean Section.
Gong, X; Wu, X, 2022
)
1.9
"To investigate the effects of carboprost tromethamine combined with oxytocin on infant outcome, postpartum hemorrhage, and uterine involution in parturients undergoing cesarean section."( Cohort Study Summary of the Effects of Carboprost Tromethamine Combined with Oxytocin on Infant Outcome, Postpartum Hemorrhage and Uterine Involution of Parturients Undergoing Cesarean Section.
Gong, X; Wu, X, 2022
)
1.28
"Carboprost aminobutyriol combined with carbestatin can effectively prevent the occurrence of bleeding after cesarean section, improve uterine involution, and improve neonatal birth quality, which is worth popularizing."( Cohort Study Summary of the Effects of Carboprost Tromethamine Combined with Oxytocin on Infant Outcome, Postpartum Hemorrhage and Uterine Involution of Parturients Undergoing Cesarean Section.
Gong, X; Wu, X, 2022
)
2.43

Dosage Studied

A normal-phase high-performance liquid chromatographic method was used for the determination of methyl carboprost and acid-catalyzed degradation products in a polymer-based, controlled release dosage form.

ExcerptRelevanceReference
" Of 815 women treated according to the dosage regimen described here, 78."( Induction of abortion by intramuscular administration of (15S)-15-methyl PGF2 alpha. An overview of 815 cases.
Lamborn, KR; Schwallie, PC, 1979
)
0.26
" Also, the intravenous route allows for adjusted drug dosage and stopping the procedure in the event of an undesirable reaction."( Midtrimester abortion with intravenous administration of 15 methyl prostaglandin F2 alpha.
Devi, PK; Kochhar, U; Mapa, MK; Raghavan, KS, 1982
)
0.26
"A normal-phase high-performance liquid chromatographic method was used for the determination of methyl carboprost and acid-catalyzed degradation products in a polymer-based, controlled release dosage form."( High-performance liquid chromatographic determination of acid-catalyzed degradation products of methyl carboprost in a polymeric controlled-release device.
DeZwaan, J; Plaisted, SM; Snider, BG, 1984
)
0.7
" The dosage regime was 250 microgram of the prostaglandin analogue every 1 to 3 hours."( Termination of pregnancy by intramuscular administration of 15 (S)-15-methyl-prostaglandin in F2 alpha.
Decoster, JM; Parewijck, W; Thiery, M, 1980
)
0.26
" The average total dosage of 15-methyl-PGF 2 alpha was 2075 micrograms (or 8,3 injections) per patient."( Termination of mid-trimester pregnancy with intramuscular 15-(S)-15-,methyl-prostaglandin F2 alpha.
Bloch, B; Rush, JM; Tsalacopoulos, G, 1982
)
0.26
" The average total dosage of 15-methyl-PGF2 alpha was 1250 micrograms (or 5 injections) per patient."( Missed abortion treated with intramuscular 15-(S)-15-methyl-prostaglandin F2 alpha.
Bloch, B; Rush, JM; Tsalacopoulos, G, 1982
)
0.26
" These include optimal dosage, dosing schedule, duration of treatment, and comparative efficacy with other agents."( Treatment of cyclophosphamide-induced hemorrhagic cystitis with prostaglandins.
Chandler, SW; Ippoliti, CM; Miller, LJ, 1994
)
0.29
" This raised concerns over the stability and applied dosage in the in-house infusion preparations."( Method to determine stability and recovery of carboprost and misoprostol in infusion preparations.
Chu, KO; Pang, CP; Rogers, MS; Wang, CC, 2007
)
0.6
"Myometrial strips obtained from labouring (with or without oxytocin augmentation) and non-labouring women undergoing Cesarean deliveries were subjected to a dose-response testing with oxytocin, ergonovine, PGF2α, or misoprostol (10(-10) M to 10(-5) M)."( Comparative efficacy of uterotonic agents: in vitro contractions in isolated myometrial strips of labouring and non-labouring women.
Balki, M; Carvalho, JC; Erik-Soussi, M; Kingdom, J, 2014
)
0.4
" They were then washed and subjected to dose-response testing with oxytocin, ergonovine, or carboprost (10 to 10 M), either alone or in combination with a fixed low-dose (10 M) (LDOx) or high-dose (10 M) (HDOx) oxytocin."( The Contractile Effects of Oxytocin, Ergonovine, and Carboprost and Their Combinations: an In Vitro Study on Human Myometrial Strips.
Balki, M; Carvalho, JCA; Erik-Soussi, M; Kingdom, J; Ramachandran, N, 2015
)
0.89
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
oxytocicA drug that stimulates contraction of the myometrium. Oxytocics are used to induce labour, obstetric at term, to prevent or control postpartum or postabortion haemorrhage, and to assess foetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (abortifacients).
abortifacientA chemical substance that interrupts pregnancy after implantation.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydroxy monocarboxylic acidAny monocarboxylic acid which also contains a separate (alcoholic or phenolic) hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (224)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990125 (55.80)18.7374
1990's39 (17.41)18.2507
2000's26 (11.61)29.6817
2010's20 (8.93)24.3611
2020's14 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.58 (24.57)
Research Supply Index5.61 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index123.61 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (71.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials41 (17.75%)5.53%
Reviews13 (5.63%)6.00%
Case Studies27 (11.69%)4.05%
Observational0 (0.00%)0.25%
Other150 (64.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Administration Time Point of Carboprost Methylate and Effects on Perioperative Complications and Cervical Ripening Effect in Artificial Abortion [NCT05834361]120 participants (Actual)Interventional2022-01-01Completed
Impact of Uterotonic Agents on Isolated Human Myometrium [NCT00989027]56 participants (Actual)Interventional2007-06-30Completed
Comparison of Intravenous Ergonovine With Intramuscular Carboprost, Both in Combination With Oxytocin Infusion, During Cesarean Section for Failure to Progress in Labor: A Double-blinded Placebo-controlled Randomized Controlled Trial [NCT01869556]105 participants (Actual)Interventional2013-06-04Completed
A Randomized Controlled Trial of Standardized Versus Conventional Oxytocin and Uterotonic Agent Use for Cesarean Delivery [NCT01549223]Phase 460 participants (Actual)Interventional2011-04-30Completed
Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial [NCT03584854]Phase 4100 participants (Actual)Interventional2019-03-01Active, not recruiting
Intrauterine Misoprostol With Active Management of Labour Versus Active Management of Labour for Prevebtion of Postpartum Hemorage in Cesarean Section ,Randomized Controlled Trial [NCT03390010]Phase 1300 participants (Actual)Interventional2017-12-28Completed
Carboprost Tromethamine (Hemabate) for Resection of Fibroids-a Pilot Study [NCT05518812]Early Phase 130 participants (Anticipated)Interventional2022-07-12Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01549223 (2) [back to overview]1. Amount of Oxytocin to Obtain Satisfactory Uterine Tone.
NCT01549223 (2) [back to overview]Side Effects (Hypotension, Flushing, Nausea and Emesis) Associated With Uterotonic Drug Use

1. Amount of Oxytocin to Obtain Satisfactory Uterine Tone.

Will measure total amount of oxytocin to achieve satisfactory uterine tone, as determined by the operating obstetrician. (NCT01549223)
Timeframe: Up to 15 min from time of infant delivery

InterventionIU (Mean)
Standard Care Group8.4
Protocol Group4.0

[back to top]

Side Effects (Hypotension, Flushing, Nausea and Emesis) Associated With Uterotonic Drug Use

Number of subjects experiencing hypotension, flushing, nausea, and emesis reported after administration of uterotonic agents. (NCT01549223)
Timeframe: Up to 15 min from time of infant delivery

InterventionParticipants (Count of Participants)
Standard Care Group3
Protocol Group2

[back to top]